Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Alcohol Clin Exp Res ; 29(8): 1390-401, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16131846

ABSTRACT

BACKGROUND: Previous research has implicated the alpha5-containing GABAA receptors of the hippocampus in the reinforcing properties of alcohol. In the present study, a selective GABAA alpha5 benzodiazepine inverse agonist (e.g., RY 023) was used in a series of in vivo and in vitro studies to determine the significance of the alpha5-receptor in the neurobehavioral actions of alcohol. METHODS: In experiment one, systemic injections of RY 023 (1 to 10 mg/kg IP) dose-dependently reduced ethanol-maintained responding by 52% to 86% of controls, whereas bilateral hippocampal infusions (0.3 to 20 microg) reduced responding by 66% to 84% of controls. Saccharin responding was reduced only with the highest intraperitoneal (e.g., 10 mg) and microinjected (e.g., 20 microg) doses. In experiment two, RY 023 (3.0 to 15 mg/kg IP) reversed the motor-impairing effects of a moderate dose of alcohol (0.75 g/kg) on an oscillating bar task in the absence of intrinsic effects. In the open field, RY 023 (3.0 to 7.5 mg/kg) produced intrinsic effects alone but attenuated the suppression of the 1.25 g/kg ethanol dose. Because the diazepam-insensitive receptors (e.g., alpha4 and alpha6) have been suggested to play a role in alcohol motor impairing and sedative actions, experiment three compared the efficacy of RY 023 with Ro 15-4513 and two prototypical benzodiazepine antagonists (e.g., flumazenil and ZK 93426) across the alpha4beta3gamma2-, alpha5beta3gamma2-, and alpha6beta3gamma2-receptor subtypes in Xenopus oocytes. RESULTS: RY 023 produced classic inverse agonism at all receptor subtypes, whereas Ro15-4513 and the two antagonists displayed a neutral or agonistic profile at the diazepam-insensitive receptors. CONCLUSIONS: Overall, the results extend our previous findings by demonstrating that an alpha5-subtype ligand is capable of attenuating not only the rewarding action of alcohol but also its motor impairing and sedative effects. We propose that these actions are mediated in part by the alpha5-receptors of the hippocampus. The hippocampal alpha5-receptors could represent novel targets in understanding the neuromechanisms regulating the neurobehavioral actions of alcohol in humans.


Subject(s)
Alcohol Deterrents/pharmacology , Benzodiazepines/agonists , Ethanol/toxicity , GABA Antagonists/pharmacology , GABA-A Receptor Agonists , Hippocampus/drug effects , Animals , Arousal/drug effects , Dose-Response Relationship, Drug , Motor Activity/drug effects , Rats , Rats, Inbred Strains
2.
Psychopharmacology (Berl) ; 172(4): 455-62, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14666398

ABSTRACT

RATIONALE: Previously, we reported that the GABA(A)receptor containing alpha(5)subunit played a significant role in the reinforcing actions of EtOH in rats selectively bred to consume alcohol. However, the role of the alpha(5) receptor in regulating the neurobehavioral effects of EtOH in outbred rats is not known. OBJECTIVE: In the present study, RY024, a novel benzodiazepine (BDZ) inverse agonist with high affinity (K(d) approximately 0.40 nM) and selectivity (approximately 67.3-fold) for the alpha(5)receptor, was investigated for its capacity to antagonize EtOH's reinforcing, motor impairing, and sedative effects in Long-Evans rats. METHODS: Rats were trained to lever press for EtOH under a fixed-ratio 1 schedule of reinforcement. Subsequent studies evaluated EtOH's motor-impairing effects in an oscillating bar task, while EtOH's sedative effects were measured in the open field. RESULTS: RY024 (0.125-3.5 mg/kg; IP) markedly reduced EtOH-maintained responding with no effects on water responding, except for the highest dose. RY024 (3.0-15 mg/kg; IP) also reversed the motor impairing effects of a moderate (0.75 g/kg), and intoxicating EtOH dose (1.25 g/kg) in the absence of intrinsic effects. Finally, RY024 (7.5 mg/kg) attenuated the sedation produced by the 1.25 g/kg EtOH dose; however, it failed to attenuate the sedation induced by the 0.75 g/kg EtOH dose. Given alone, RY024 exhibited intrinsic effects in the open field. CONCLUSION: The results suggest the GABA(A)receptor containing alpha(5)subtype plays an important role in regulating the reinforcing, motor-impairing, and sedative effects of alcohol in outbred rats.


Subject(s)
Benzodiazepines/pharmacology , Ethanol/antagonists & inhibitors , Ethanol/pharmacology , GABA-A Receptor Antagonists , Motor Activity/drug effects , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Drug Interactions , Ethanol/blood , Ligands , Male , Protein Subunits/antagonists & inhibitors , Rats , Rats, Long-Evans , Reinforcement, Psychology
3.
Neuropsychopharmacology ; 29(2): 285-99, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14603266

ABSTRACT

The exact opioid-sensitive receptors participating in EtOH-seeking behaviors remains unclear. Previous studies have reported higher densities of micro-opioid receptor binding in the nucleus accumbens (NACC) of P relative to NP rats; however, no differences were seen in delta-receptor binding. In contrast to the NACC, substantially lower levels of micro-receptor binding have been observed in the ventral tegmental area (VTA) of both P and NP rats, albeit no line differences have been observed. In the present study, opioid receptors in the NACC, VTA, and hippocampus were evaluated for their capacity to regulate both EtOH- and saccharin-motivated behaviors in the genetically selected alcohol-preferring (P) rat. To accomplish this, nalmefene, an opiate antagonist with preferential binding affinity for the micro-opioid receptor was unilaterally or bilaterally infused during concurrent availability of 1 h daily EtOH (10% v/v) and saccharin (0.025 or 0.050% w/v) solutions. Rats performed under a two-lever fixed ratio (FR) schedule in which four responses on one lever produced the EtOH solution, and four on a second lever produced the saccharin solution. The results demonstrated that when responding maintained by both EtOH and saccharin are matched at basal levels, unilateral (1-60 microg) or bilateral (0.5-10 microg) microinjections of nalmefene into the NACC produced selective dose-dependent reductions on responding maintained by EtOH. Unilateral (40, 60 microg) and bilateral (10 microg) VTA infusions were also observed to selectively reduced EtOH responding; however, greater nalmefene doses were required and the magnitude of suppression on EtOH responding was markedly less compared with the NACC. The greater sensitivity of nalmefene to suppress EtOH responding in the NACC is likely due to the greater number of opioid receptors in the NACC relative to the VTA. Only bilateral infusion of the 40 microg dose in the NACC and VTA suppressed responding maintained by both EtOH and saccharin. In contrast, intrahippocampal infusions dose dependently suppressed EtOH- and saccharin-maintained responding over a range of doses (1-20 microg). The present study provides evidence that nalmefene suppresses EtOH-motivated behaviors via blockade of opioid receptors within the NACC and VTA, and under various dose conditions both reinforcer and neuroanatomical specificity can be observed.


Subject(s)
Behavior, Addictive/drug therapy , Ethanol/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/therapeutic use , Receptors, Opioid/metabolism , Reinforcement, Psychology , Saccharin/pharmacology , Animals , Brain/anatomy & histology , Brain/drug effects , Central Nervous System Depressants/pharmacology , Conditioning, Operant , Dose-Response Relationship, Drug , Female , Functional Laterality , Microinjections , Naltrexone/pharmacology , Narcotic Antagonists/therapeutic use , Rats , Rats, Inbred Strains , Receptors, Opioid/drug effects
4.
Neuropsychopharmacology ; 28(12): 2124-37, 2003 Dec.
Article in English | MEDLINE | ID: mdl-12968126

ABSTRACT

It has been hypothesized that alcohol addiction is mediated, at least in part, by specific gamma-aminobutyric acid(A) (GABA(A)) receptors within the ventral pallidum (VP). Among the potential GABA(A) receptor isoforms regulating alcohol-seeking behaviors within the VP, the GABA(A) alpha1 receptor subtype (GABA(A1)) appears pre-eminent. In the present study, we developed beta-carboline-3-carboxylate-t-butyl ester (betaCCt), a mixed agonist-antagonist benzodiazepine (BDZ) site ligand, with binding selectivity at the A1 receptor to explore the functional role of VP(A1) receptors in the euphoric properties of alcohol. The in vivo actions of betaCCt were then determined following microinfusion into the VP, a novel alcohol reward substrate that primarily expresses the A1 receptor. In two selectively bred rodent models of chronic alcohol drinking (HAD-1, P rats), bilateral microinfusion of betaCCt (0.5-40 microg) produced marked reductions in alcohol-reinforced behaviors. Further, VP infusions of betaCCt exhibited both neuroanatomical and reinforcer specificity. Thus, no effects on alcohol-reinforced behaviors were observed following infusion in the nucleus accumbens (NACC)/caudate putamen (CPu), or on response maintained by saccharin. Parenteral-administered betaCCt (1-40 mg/kg) was equally effective and selective in reducing alcohol-reinforced behaviors in P and HAD-1 rats. Additional tests of locomotor activity revealed that betaCCt reversed the locomotor sedation produced by both chlordiazepoxide (10 mg/kg) and EtOH (1.25 g/kg), but was devoid of intrinsic effects when given alone. Studies in recombinant receptors expressed in Xenopus oocytes revealed that betaCCt acted as a low-efficacy partial agonist at alpha3beta3gamma2 and alpha4beta3gamma2 receptors and as a low-efficacy inverse agonist at alpha1beta3gamma2, alpha2beta3gamma2, and alpha5beta3gamma2 receptors. The present study indicates that betaCCt is capable of antagonizing the reinforcing and the sedative properties of alcohol. These anti-alcohol properties of betaCCt are primarily mediated via the GABA(A1) receptor. betaCCt may represent a prototype of a pharmacotherapeutic agent to effectively reduce alcohol drinking behavior in human alcoholics.


Subject(s)
Alcohols/pharmacology , Globus Pallidus/drug effects , Receptors, GABA-A/metabolism , Reinforcement, Psychology , Alcoholism , Animals , Body Weight/drug effects , Carbolines/blood , Carbolines/chemistry , Carbolines/pharmacology , Conditioning, Operant/drug effects , Disease Models, Animal , Drug Administration Routes , Drug Interactions , Ethanol/pharmacology , Female , GABA-A Receptor Agonists , GABA-A Receptor Antagonists , Globus Pallidus/physiology , Membrane Potentials/drug effects , Microinjections , Motor Activity/drug effects , Neostriatum/drug effects , Oocytes , Patch-Clamp Techniques , Protein Subunits , Rats , Receptors, GABA-A/drug effects , Saccharin/pharmacology , Self Administration , Sucrose/pharmacology , Sweetening Agents/pharmacology , Time Factors , Xenopus , gamma-Aminobutyric Acid/pharmacology
5.
J Neurosci ; 22(9): 3765-75, 2002 May 01.
Article in English | MEDLINE | ID: mdl-11978852

ABSTRACT

We investigated the potential role of the alpha1-containing GABA(A) receptor in regulating the reinforcing properties of alcohol. To accomplish this, we developed 3-propoxy-beta-carboline hydrochloride (3-PBC), a mixed agonist-antagonist benzodiazepine site ligand with binding selectivity at the alpha1 receptor. We then tested the capacity of 3-PBC to block alcohol-maintained responding in the ventral pallidum (VP), a novel alcohol reward substrate, which primarily expresses the alpha1-receptor isoform. Our results demonstrated that bilateral microinfusion of 3-PBC (0.5-40 microg) in the anterior and medial VP produced marked reductions in alcohol-maintained responding in a genetically selected rodent model of alcohol drinking. The VP infusions showed both neuroanatomical and reinforcer specificity because no effects were seen in sites dorsal to the VP (e.g., nucleus accumbens, caudate putamen). The saccharin-maintained responding was reduced only with the highest dose (40 microg). Parenteral injections of 3-PBC (1-20 mg/kg) also showed a similar selectivity on alcohol-maintained responding. Complementary in vitro studies revealed that 3-PBC exhibited a low partial agonist efficacy profile at recombinant diazepam-sensitive receptors (e.g., alpha1beta3gamma2, alpha2beta3gamma, and alpha3beta3gamma2). The selective suppression of 3-PBC on alcohol-maintained responding after central and parenteral administrations, together with its low-efficacy agonist profile, suggest that the reduction in alcohol-maintained behaviors was not attributable to a general suppression on consummatory behaviors. These results demonstrate that the alpha1-containing GABA(A) receptors in both the anterior and medial VP are important in regulating the reinforcing properties of alcohol. These receptors represent novel targets in the design and development of pharmacotherapies for alcohol-dependent subjects.


Subject(s)
Alcoholism , Ethanol/pharmacology , Globus Pallidus/metabolism , Receptors, GABA-A/metabolism , Reinforcement, Psychology , Alcoholism/drug therapy , Alcoholism/metabolism , Animals , Appetitive Behavior/drug effects , Behavior, Animal/drug effects , Benzodiazepines/antagonists & inhibitors , Binding, Competitive/drug effects , Carbolines/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Routes , GABA Antagonists/administration & dosage , GABA Modulators/administration & dosage , Globus Pallidus/drug effects , Ligands , Male , Microinjections , Oocytes/metabolism , Patch-Clamp Techniques , Protein Isoforms/drug effects , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Subunits , RNA, Complementary/administration & dosage , Rats , Rats, Inbred Strains , Receptors, GABA-A/drug effects , Receptors, GABA-A/genetics , Recombinant Proteins/drug effects , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Synaptosomes/chemistry , Synaptosomes/drug effects , Synaptosomes/metabolism , Xenopus laevis
SELECTION OF CITATIONS
SEARCH DETAIL
...